Received Jun 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | GC3N4 | — |
Engerix-B Pediatric dose administered to an adult patient; Engerix-B Pediatric dose administered to an adult patient; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 39-year-old male patient who received HBV (Engerix B pediatric) suspension for injection in pre-filled syringe (batch number GC3N4 with expiry date 04-AUG-2026) for prophylaxis. On 03-JUN-2026, the patient received Engerix B pediatric. On 03-JUN-2026, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Engerix-B Pediatric dose administered to an adult patient) and underdose (Verbatim: Engerix-B Pediatric dose administered to an adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-JUN-2026 Nurse reported that a 39 year-old patient received an Engerix-B pediatric dose, and asked for recommendations on this situation.